ZTS:NYE-Zoetis Inc. Class A

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing

USD 97.93

Change

0.00 (0.00)%

Market Cap

USD 24.45B

Volume

1.40M

Analyst Target

USD 102.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-03-25 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
SCYB Schwab Strategic Trust

+0.04 (+0.08%)

N/A

ETFs Containing ZTS

ZEAT:CA BMO Global Agriculture ET.. 9.04 % 0.00 %

N/A

CAD 3.82M
PETZ:LSE 7.07 % 0.00 %

N/A

N/A
KATZ:XETRA 7.03 % 0.00 %

N/A

N/A
PETZ:SW 7.03 % 0.00 %

N/A

N/A
XMEM:SW Xtrackers MSCI Emerging M.. 5.31 % 0.00 %

N/A

USD 0.67B
C9DF:XETRA Frankfurter UCITS-ETF - M.. 4.11 % 0.00 %

-0.52 (-1.19%)

N/A
CVGB:LSE VanEck Smart Home Active .. 3.47 % 0.00 %

+0.02 (+-1.19%)

USD 0.01B
CAVE:LSE VanEck Smart Home Active .. 3.47 % 0.00 %

+0.04 (+-1.19%)

USD 0.01B
WHCS:SW iShares MSCI World Health.. 3.29 % 0.00 %

N/A

USD 1.07B
VCAV:XETRA VanEck Smart Home Active .. 3.19 % 0.00 %

+0.03 (+-1.19%)

USD 0.01B
CAVE:SW VanEck Smart Home Active .. 3.19 % 0.00 %

N/A

USD 0.01B
CBUF:XETRA iShares MSCI World Health.. 2.78 % 0.00 %

N/A

USD 1.13B
EKLD:PA BNP Paribas Easy - MSCI U.. 2.08 % 0.00 %

N/A

USD 0.40B
EKUS:PA BNP Paribas Easy MSCI USA.. 2.08 % 0.00 %

+0.02 (+-1.19%)

USD 0.50B
EKUS:XETRA BNP Paribas Easy MSCI USA.. 2.06 % 0.00 %

-0.02 (-1.19%)

USD 0.97B
ZSRM:XETRA BNP Paribas Easy MSCI USA.. 2.06 % 0.00 %

-0.01 (-1.19%)

USD 0.07B
EKLDC:PA BNP Paribas Easy MSCI USA.. 2.06 % 0.00 %

-0.02 (-1.19%)

N/A
ZSRM:F BNP Paribas Easy MSCI USA.. 2.06 % 0.00 %

-0.24 (-1.19%)

N/A
EKLD:XETRA BNP Paribas Easy MSCI USA.. 2.04 % 0.00 %

+0.02 (+-1.19%)

USD 0.53B
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

-0.09 (-1.19%)

USD 0.69B
MOO VanEck Agribusiness ETF 0.00 % 0.54 %

+0.48 (+-1.19%)

USD 0.81B
IVFGC 0.00 % 0.00 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

-0.06 (-1.19%)

CAD 0.05B
HWF:CA 0.00 % 0.00 %

N/A

N/A
VLQ:CA 0.00 % 0.40 %

N/A

N/A
PSWU:LSE 0.00 % 0.00 %

N/A

N/A
XMEM:LSE Xtrackers MSCI Emerging M.. 0.00 % 0.00 %

+28.50 (+-1.19%)

USD 0.66B
PWC:PA 0.00 % 0.00 %

N/A

N/A
6PSH:F 0.00 % 0.00 %

N/A

N/A
6PSH:XETRA 0.00 % 0.00 %

N/A

N/A
DUAL 0.00 % 0.00 %

N/A

N/A
DIET 0.00 % 0.00 %

N/A

N/A
STNC Stance Equity ESG Large C.. 0.00 % 0.00 %

+0.17 (+-1.19%)

USD 0.12B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.48% 62% D 72% C
Dividend Return 0.19% 9% A- 7% C-
Total Return 14.68% 62% D 70% C-
Trailing 12 Months  
Capital Gain 21.50% 74% C 90% A-
Dividend Return 0.67% 8% B- 8% B-
Total Return 22.17% 68% D+ 88% B+
Trailing 5 Years  
Capital Gain 234.69% 100% F 98% N/A
Dividend Return 6.89% 27% F 23% F
Total Return 241.58% 100% F 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 26.02% 100% F 95% A
Dividend Return 26.85% 100% F 95% A
Total Return 0.82% 33% F 18% F
Risk Return Profile  
Volatility (Standard Deviation) 18.76% 53% F 38% F
Risk Adjusted Return 143.11% 100% F 96% N/A
Market Capitalization 24.45B 59% D- 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.00 33% 17%
Price/Book Ratio 22.21 4% 3%
Price / Cash Flow Ratio 6.64 4% 13%
Price/Free Cash Flow Ratio 32.53 22% 14%
Management Effectiveness  
Return on Equity 69.38% 96% 96%
Return on Invested Capital 24.25% 89% 88%
Return on Assets 14.83% 100% 95%
Debt to Equity Ratio 276.00% 12% 10%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.